Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Blinatumomab Is Cost-Effective Compared to Standard Chemotherapy for Children with High Risk Relapses of Acute Lymphoblastic Leukemia: A Cost-Effectiveness Analysis Using Population-Based Healthcare Data

Petros Pechlivanoglou, Linda Luu, Qing Li, Paul J. Gibson, Uma H. Athale, Mylene Bassal, Vicky R. Breakey, Serina Patel, Jason Pole, Rinku Sutradhar, Laura Wheaton, Nicole Mittmann, Sumit Gupta

Blood (2021) 138 (Supplement 1): 565.

https://doi.org/10.1182/blood-2021-154193

Published: 2021

Journal Articles

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 27–30.

https://doi.org/10.1182/blood-2020-136692

Published: 2020

Journal Articles

High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada

Lee Mozessohn, MD, Matthew Cheung, MD MS, FRCP, Nicole Mittmann, PhD, Craig C. Earle, MD, Ning Liu, Rena Buckstein, MD FRCPC

Blood (2018) 132 (Supplement 1): 834.

https://doi.org/10.1182/blood-2018-99-110223

Published: 2018

Journal Articles

Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Long-Term Remission

Matthew C Cheung, MD SM, FRCPC, Nicole Mittmann, PhD, Craig Earle, MD MSc., Farah Rahman, Ning Liu, Simron Singh, MD MPH, FRCPC

Blood (2016) 128 (22): 692.

https://doi.org/10.1182/blood.V128.22.692.692

Published: 2016

Journal Articles

Utilization and Costs of Red Blood Cell Transfusions Pre- and Post-Azacitidine in Higher-Risk Myelodysplastic Syndromes

Eric Tseng, MD, Soojin Seung, B.Sc, Nicole Mittmann, PhD, Jeannie Callum, MD, FRCPC, Richard A. Wells, MD, DPhil, Tony Kim, M.A., Rena Buckstein, MD

Blood (2012) 120 (21): 4261.

https://doi.org/10.1182/blood.V120.21.4261.4261

Published: 2012

Journal Articles

Deriving Health Utility Values From a Health-Related Quality of Life Instrument in Non-Hodgkin Lymphoma Patients

Nina Lathia, MSc, Pierre K Isogai, B.Sc, Jeffrey S Hoch, PhD, Carlo De Angelis, PharmD, Matthew Cheung, MD, FRCPC, Scott Walker, MScPhm, Nicole Mittmann, PhD

Blood (2011) 118 (21): 2065.

https://doi.org/10.1182/blood.V118.21.2065.2065

Published: 2011

Journal Articles

Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL)

Nicole Mittmann, PhD, Matthew Cheung, MD, FRCPC, Pierre K Isogai, B.Sc, Refik Saskin, Ning Liu, Jeffrey S Hoch, Natasha Leighl, BSc, MD, MSc, Maureen E Trudeau, William K Evans, Katie N Dainty, Craig C. Earle, MD, MSc

Blood (2011) 118 (21): 2068.

https://doi.org/10.1182/blood.V118.21.2068.2068

Published: 2011

Journal Articles

Long-Term Oral Anticoagulant Management Associated with Routine Medical Care (RMC) In Patients with Non-Valvular Atrial Fibrillation (NVAF) In Canada,

Rita Selby, MBBS, MSc, FRCPC, Nicole Mittmann, PhD, Pierre K Isogai, B.Sc, Lisa Kaus, Marika Koo, BSc, Faith Sealey

Blood (2011) 118 (21): 4192.

https://doi.org/10.1182/blood.V118.21.4192.4192

Published: 2011

Journal Articles

Trends in the Incidence of HIV-Related Hematologic Malignancies in the Era of Combination Antiretroviral Therapy and Predictors of HIV-Related Non-Hodgkin's Lymphoma Development and Survival.

Linda R Taggart, MD, Pierre K Isogai, B.Sc, Nancy Risebrough, B.A., Nicole Mittmann, MSc, PhD, Anita R Rachlis, MD, Kevin R Imrie, MD, Matthew C Cheung, MD

Blood (2009) 114 (22): 1916.

https://doi.org/10.1182/blood.V114.22.1916.1916

Published: 2009

Journal Articles

Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis against Febrile Neutropenia in Lymphoma Patients Receiving R-CHOP Chemotherapy.

Nina Lathia, MSc, Pierre K Isogai, B.Sc, Scott Walker, MScPhm, Matthew C Cheung, MD, Murray Krahn, MD, MSc, Carlo DeAngelis, PharmD, Nicole Mittmann, MSc, PhD

Blood (2009) 114 (22): 2475.

https://doi.org/10.1182/blood.V114.22.2475.2475

Published: 2009

Journal Articles

Economic Analysis of Alemtuzumab in Fludarabine-Refractory and Relapsed Chronic Lymphocytic Leukemia in Canada

Pierre K Isogai, B.Sc, Matthew Cheung, MD, Nicole Mittmann, MSc, PhD

Blood (2008) 112 (11): 2375.

https://doi.org/10.1182/blood.V112.11.2375.2375

Published: 2008

Journal Articles

The Cost of HIT-Safe Anticoagulant Use at a Tertiary Care, Adult, Academic Hospital.

Natasha Nanwa, MSc, Nicole Mittmann, MSc, PhD, Sandra Knowles, BScPhm, Claudia Bucci, BScPhm, PharmD, Rita Selby, MBBS, FRCPC, Neil Shear, MD, FRCPC, Scott Walker, MScPhm, William H. Geerts, MD, FRCPC

Blood (2008) 112 (11): 1293.

https://doi.org/10.1182/blood.V112.11.1293.1293

Published: 2008

Journal Articles

Comprehensiveness of Quality of Life Instruments in Capturing Concerns Related to Chemotherapy-Induced Neutropenia

Lathi A Nina, MSc, Pierre Isogai, BSc, Nicole Mittmann, PhD, Carlo DeAngelis, PharmD, Matthew Cheung, Knowles Sandra, Eugenia Piliotis, Neil Shear, Scott Walker

Blood (2008) 112 (11): 1311.

https://doi.org/10.1182/blood.V112.11.1311.1311

Published: 2008

Journal Articles

The Direct Medical Costs Associated with Suspected and Confirmed Cases of Heparin-Induced Thrombocytopenia.

Natasha Nanwa, BSc, Nicole Mittmann, MSc, PhD, Sandra Knowles, BScPhm, Rita Selby, MD, Neil Shear, MD, Scott Walker, BScPhm, MSc, William Geerts, MD

Blood (2007) 110 (11): 972.

https://doi.org/10.1182/blood.V110.11.972.972

Published: 2007

Journal Articles

Discrimination of Health States in Follicular Lymphoma with Utilities Derived from the EuroQOL EQ5D Instrument.

Jessica D. Friedlich, Matthew C. Cheung, MD, Kevin R. Imrie, MD, Brigette Hales, MSc, Nicole Mittmann, PhD, Rena Buckstein, MD

Blood (2006) 108 (11): 3329.

https://doi.org/10.1182/blood.V108.11.3329.3329

Published: 2006

Journal Articles

The Potential for Lost Productivity and Daily Activity Impairment in Patients with Follicular (FL) and Other Indolent Non-Hodgkin’s Lymphoma (NHL).

Matthew C. Cheung, MD, Kevin R. Imrie, MD, Jessica Friedlich, Rena Buckstein, MD, Lisa K. Hicks, MD, Yael Zaretsky, MD, Brigette Hales, MSc, Eugenia Piliotis, MD, Nicole Mittmann, PhD

Blood (2006) 108 (11): 344.

https://doi.org/10.1182/blood.V108.11.344.344

Published: 2006

NARROW

Blinatumomab Is Cost-Effective Compared to Standard Chemotherapy for Children with High Risk Relapses of Acute Lymphoblastic Leukemia: A Cost-Effectiveness Analysis Using Population-Based Healthcare Data

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada

Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Long-Term Remission

Utilization and Costs of Red Blood Cell Transfusions Pre- and Post-Azacitidine in Higher-Risk Myelodysplastic Syndromes

Deriving Health Utility Values From a Health-Related Quality of Life Instrument in Non-Hodgkin Lymphoma Patients

Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL)

Long-Term Oral Anticoagulant Management Associated with Routine Medical Care (RMC) In Patients with Non-Valvular Atrial Fibrillation (NVAF) In Canada,

Trends in the Incidence of HIV-Related Hematologic Malignancies in the Era of Combination Antiretroviral Therapy and Predictors of HIV-Related Non-Hodgkin's Lymphoma Development and Survival.

Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis against Febrile Neutropenia in Lymphoma Patients Receiving R-CHOP Chemotherapy.

Economic Analysis of Alemtuzumab in Fludarabine-Refractory and Relapsed Chronic Lymphocytic Leukemia in Canada

The Cost of HIT-Safe Anticoagulant Use at a Tertiary Care, Adult, Academic Hospital.

Comprehensiveness of Quality of Life Instruments in Capturing Concerns Related to Chemotherapy-Induced Neutropenia

The Direct Medical Costs Associated with Suspected and Confirmed Cases of Heparin-Induced Thrombocytopenia.

Discrimination of Health States in Follicular Lymphoma with Utilities Derived from the EuroQOL EQ5D Instrument.

The Potential for Lost Productivity and Daily Activity Impairment in Patients with Follicular (FL) and Other Indolent Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only